At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
bapineuzumab +2 moredrug
Likely dose
bapineuzumab 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD
In Brief
A Phase 2 clinical trial evaluating bapineuzumab and placebo for Alzheimer Disease. Completed, enrolled 79 participants across 17 sites.
Detailed Summary
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartNov 2008
Primary CompletionOct 2010
TodayJul 2026
First PostedApr 21, 2008
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.2 years ago
Interventions
bapineuzumabdrug
5 mg bapineuzumab subcutaneous injection once per week for 6 months
bapineuzumabdrug
10 mg bapineuzumab subcutaneous injection once per week for 6 months
placebodrug
Placebo subcutaneous injection once per week for 6 months